Qin Wei, Qi Yazhou, Li Qianwen, Wang Bei, Wang Jingmiao, Ge Xueke, Li Yanhong, Zhang Xinyue, Liu Kuan
Internal Medicine of Integrated Chinese and Western Medicine, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Department of Gynecology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Drug Des Devel Ther. 2025 Aug 27;19:7381-7392. doi: 10.2147/DDDT.S524181. eCollection 2025.
Endometrial cancer, a common malignancy of the female reproductive system, has a rising incidence and complex clinical management due to its diverse molecular subtypes. This review examines the molecular mechanisms underlying EC, particularly the roles of the Bcl-2 family in apoptosis regulation and estrogen receptor signaling in tumor progression. We explore pharmacological interventions targeting these pathways, including BH3 mimetics and selective estrogen receptor modulators, which show promise but face challenges such as resistance and adverse effects. Additionally, we highlight the potential of natural compounds like curcumin, paclitaxel, and Ganoderma lucidum polysaccharides as adjunctive therapies, demonstrating efficacy in preclinical studies and early-phase clinical trials. This review aims to provide insights into the development of personalized therapeutic strategies for EC and to identify opportunities for optimizing clinical outcomes in future treatments.
子宫内膜癌是女性生殖系统常见的恶性肿瘤，由于其分子亚型多样，发病率呈上升趋势，临床管理也较为复杂。本综述探讨了子宫内膜癌的分子机制，特别是Bcl-2家族在细胞凋亡调节中的作用以及雌激素受体信号在肿瘤进展中的作用。我们研究了针对这些途径的药物干预措施，包括BH3模拟物和选择性雌激素受体调节剂，这些药物显示出一定前景，但面临耐药性和不良反应等挑战。此外，我们强调了姜黄素、紫杉醇和灵芝多糖等天然化合物作为辅助治疗的潜力，这些化合物在临床前研究和早期临床试验中已证明具有疗效。本综述旨在深入了解子宫内膜癌个性化治疗策略的发展，并确定在未来治疗中优化临床结果的机会。
